4.7 Article

pH-redox responsive cascade-targeted liposomes to intelligently deliver doxorubicin prodrugs and lonidamine for glioma

期刊

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114281

关键词

Glioma; Multi-functional; pH/redox responsive; Doxorubicin; Lonidamine; Liposome

资金

  1. National Natural Science Foundation of China [81773577, 81903448]
  2. Sichuan Science and Technology Program [2018JY0537, 2020YJ0221]
  3. Fundamental Research Funds for the Universities of Henan Province [NSFRF210319]
  4. Henan Medical Science and Technology Joint Building Program [LHGJ20210925]
  5. Henan Key Project of Research and Development Plan (Science and Technology) [222102310091]

向作者/读者索取更多资源

In this study, novel cascadetargeted liposomes (Lip-TPGS) were designed and prepared for synergistic treatment of glioma. These liposomes could intelligently deliver redox-sensitive doxorubicin prodrugs and a chemotherapeutic sensitizer, providing a promising drug delivery system with potential advantages in inhibiting proliferation, promoting apoptosis, inducing mitochondria dysfunction, inhibiting migration and invasion, prolonging survival time, and reducing toxicity.
To synergistically treat glioma with a combination chemotherapy, we design and prepare novel cascadetargeted liposomes (Lip-TPGS) using glucose and triphenylphosphonium (TPP) as targeting moieties, which could intelligently deliver redox-sensitive doxorubicin (DOX) prodrugs (SDOX) and chemotherapeutic sensitizer lonidamine (LND). The pH-responsive ligand Chol-TPG modified by PEGylated glucose can overcome the blood-brain barrier and reach tumor cells. Combined with the modification of mitochondria targeting ligand (Chol-TPP), Lip-TPGS are endowed with pH-responsive charge regulation function and multi-stage targeting abilities. After triggered by the excessive glutathione in tumor cells, Lip-TPGS could sufficiently release the parent drugs DOX, which would significantly reduce side effects without compromising anti-glioma efficacy. Therefore, Lip-TPGS possess these characteristics: good pharmacokinetic behavior, superior brain targeting ability, specific tumor recognition and internalization capability, and strong endo/lysosome escaping and mitochondria targeting potential. Furthermore, LipTPGS exhibit significant advantages on anti-glioma by inhibiting proliferation, promoting apoptosis, inducing mitochondria dysfunction, inhibiting migration and invasion, prolonging the survival time, narrowing tumor areas, limiting lung metastasis, and reducing toxicity to normal organs. In summary, Lip-TPGS, with cascade targeting abilities from tissue/cell to organelle levels and highly controlled drug release properties, would become a promising drug delivery system for glioma treatment. (C) 2022 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据